These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7151866)

  • 21. Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice.
    Joshi VV; Balsara JJ; Jadhav JH; Chandorkar AG
    Eur J Pharmacol; 1981 Feb; 69(4):499-502. PubMed ID: 6113966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats.
    Ståhle L; Ungerstedt U
    Eur J Pharmacol; 1984 Feb; 98(2):307-10. PubMed ID: 6714314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of apomorphine-induced climbing behaviour in mice by d-LSD.
    Sovilla JY; Magistretti P; Schorderet M
    Prog Neuropsychopharmacol; 1979; 3(5-6):503-11. PubMed ID: 401002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
    Van Ree JM; Elands J; Király I; Wolterink G
    Eur J Pharmacol; 1989 Aug; 166(3):441-52. PubMed ID: 2572429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats.
    Bagetta G; De Sarro G; Priolo E; Nisticò G
    Br J Pharmacol; 1988 Nov; 95(3):860-6. PubMed ID: 2974741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
    Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
    J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations in behavioral responses to dopamine agonists in olfactory bulbectomized mice: relationship to changes in the striatal dopaminergic system.
    Takahashi K; Nakagawasai O; Nemoto W; Nakajima T; Arai Y; Hisamitsu T; Tan-No K
    Psychopharmacology (Berl); 2016 Apr; 233(7):1311-22. PubMed ID: 26856855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of apomorphine-induced climbing behavior by estradiol.
    Fung YK; Brueggemeier RW; Uretsky NJ
    Pharmacol Biochem Behav; 1986 Jan; 24(1):139-41. PubMed ID: 3945658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the intracerebral injection technique to elucidate mechanisms of apomorphine climbing and its antagonism in the mouse.
    Costall B; Naylor RJ; Nohria V
    Psychopharmacology (Berl); 1981; 73(1):91-4. PubMed ID: 6785798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of atrial natriuretic peptide on apomorphine-induced stereotyped cage-climbing behavior in mice.
    Bidzseranova A; Gueron J; Tóth G; Penke B; Telegdy G
    Eur J Pharmacol; 1992 Feb; 211(3):411-4. PubMed ID: 1352255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of MK-801 on contextual sensitization to climbing behavior and on development of tolerance to hypothermia induced by a single high dose of apomorphine.
    Yun JS; Kim HS; Lee MK; Oh KW; Jang CG; Park WK; Seong YH; Lee SC; Oh SK
    Pharmacol Res; 2001 Dec; 44(6):473-9. PubMed ID: 11735353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
    Khisti RT; Deshpande LS; Chopde CT
    Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction in motor responding of the mouse by actions of dopamine agonists in the midbrain.
    Bradbury AJ; Costall B; Naylor RJ
    Neuropharmacology; 1983 Oct; 22(10):1171-6. PubMed ID: 6646352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition by bromoestrogens of the effects of estradiol on apomorphine-induced climbing behavior.
    Fung YK; Stevens JM; Palmer CW; Brueggemeier RW
    Steroids; 1987; 49(4-5):287-94. PubMed ID: 3455044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased sensitivity to dopamine agonists following a single dose of morphine or levorphanol in mice.
    Martin JR; Takemori AE
    Eur J Pharmacol; 1985 Dec; 119(1-2):75-84. PubMed ID: 3002820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
    Imperato A; Tanda G; Frau R; Di Chiara G
    J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hypomotility elicited by small doses of apomorphine seems exclusively mediated by dopaminergic systems in the nucleus accumbens.
    Radhakishun FS; Van Ree JM
    Eur J Pharmacol; 1987 May; 137(1):41-7. PubMed ID: 3609134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of dopamine receptor stimulation on the motor and stereotypic activities of mice with different genotypes].
    Skrinskaia IuA; Nikulina EM
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1992; 42(3):549-55. PubMed ID: 1353935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of nitric oxide on glutaminergic modulation of dopaminergic activation.
    Hong JT; Kim HC; Kim HS; Lee YM; Oh KW
    Pharmacol Res; 2005 Oct; 52(4):298-301. PubMed ID: 15939623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.